Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Insider Virgin Islands.
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
Press releases published on August 1, 2025
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 1, 2025
SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“ImageneBio”), a clinical stage biotechnology company dedicated to developing treatments for immunological/autoimmune and inflammatory (“I…
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 1, 2025
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent …
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
GlobeNewswire
·
August 1, 2025
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR …
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025
GlobeNewswire
·
August 1, 2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE Euronext Paris Code ISIN : FR 0010417345 …
NuCana Announces ADS Ratio Change
GlobeNewswire
·
August 1, 2025
EDINBURGH, United Kingdom, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announces that it will implement the Company’s previously disclosed plans to change the ratio of its American Depository Shares (“ADSs”) to …
Nanox to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
August 1, 2025
PETACH TIKVA, Israel, Aug. 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended June 30, …
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
August 1, 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an …
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire
·
August 1, 2025
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten …
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
GlobeNewswire
·
August 1, 2025
WARREN, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today released a letter to stockholders. Dear Fellow Stockholders, Tevogen has rapidly evolved from a biotechnology innovator into a dynamic …
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
GlobeNewswire
·
August 1, 2025
Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from KRHP LLC. WARREN, N.J., Aug. 01, 2025 …
As the $420B Cold Chain Booms, Ergodyne Arms the Front Lines
GlobeNewswire
·
August 1, 2025
St. Paul, MN, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Cold chain logistics is one of the fastest-growing industries in the world, projected to top $420 billion this year alone. That surge comes with rising demand for product, speed, and increasingly, gear that …
Sutter Health Showcases Groundbreaking Research at Symposium, Advancing Clinical Innovations to Deliver Real-World Solutions
GlobeNewswire
·
August 1, 2025
NORTHERN CALIF., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nearly 500 physicians, researchers, academic collaborators, medical students, residents, fellows and clinical leaders from across Sutter Health’s integrated system are gathering in Sacramento today for the …
Global Outpatient Clinics Market Sees Shift Toward Tech-Driven Patient Care
GlobeNewswire
·
August 1, 2025
Boston, Aug. 01, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Outpatient Clinics Market” is expected to grow from $4.4 trillion in 2024 to $6.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of …
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
GlobeNewswire
·
August 1, 2025
BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company,” “we,” “our” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today …
Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures
GlobeNewswire
·
August 1, 2025
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule …
IPG Health Introduces the Future of Market Research with ‘LivingMirror,’ an Always-On AI Focus Group for Healthcare
GlobeNewswire
·
August 1, 2025
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- For decades, market research has laid the foundation for deep insights around the globe helping brands connect, understand and grow. Now with the ability to combine agentic AI with robust data-driven audience …
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
GlobeNewswire
·
August 1, 2025
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, …
Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer
GlobeNewswire
·
August 1, 2025
ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief …
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
GlobeNewswire
·
August 1, 2025
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in …
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
GlobeNewswire
·
August 1, 2025
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion Arm …